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Abstract
The androgen receptor (AR) plays a critical role in the development of the normal prostate as well 
as prostate cancer. Using an integrative transcriptomic analysis of prostate cancer cell lines and 
tissues, we identified ARLNC1 (AR-regulated long non-coding RNA 1) as an important long non-
coding RNA that is strongly associated with AR signaling in prostate cancer progression. Not only 
was ARLNC1 induced by AR protein, ARLNC1 stabilized the AR transcript via RNA-RNA 
interaction. ARLNC1 knockdown suppressed AR expression, global AR signaling, and prostate 
cancer growth in vitro and in vivo. Taken together, these data support a role for ARLNC1 in 
maintaining a positive feedback loop that potentiates AR signaling during prostate cancer 
progression, and identifies ARLNC1 as a novel therapeutic target.
Keywords
androgen receptor; prostate cancer; long non-coding RNA; ARLNC1
Introduction
Long non-coding RNAs (lncRNAs) are a class of transcripts with diverse and largely 
uncharacterized biological functions1–3. Through cross-talk with chromatin, DNA, RNA 
species, and proteins, lncRNAs function via chromatin remodeling, transcriptional and post-
transcriptional regulation4–9. High-throughput RNA sequencing (RNA-Seq) has enabled the 
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identification of lncRNAs with suggested oncogenic and tumor suppressive roles, including 
involvement in the pathogenesis of prostate cancer (PCa)7,10–12. Primary PCa is often 
hormone-dependent and relies on signaling through the androgen receptor (AR); therefore, 
the majority of patients are responsive to front-line treatment with androgen deprivation 
therapy (ADT)13–15. However, approximately 20% of cases progress to an incurable stage of 
the disease known as castration-resistant prostate cancer (CRPC), which still critically relies 
on AR signaling16,17, as evidenced by the clinical benefit afforded through the use of 
enzalutamide18–21 or abiraterone22–24. While substantial efforts have been undertaken to 
identify mechanisms of sustained AR signaling in CRPC (i.e., AR mutations, AR splice 
variants, and alternative activation pathways)25–31, few studies have investigated the role of 
AR-regulated lncRNAs. Therefore, we initiated a comprehensive RNA-Seq profiling 
investigation of AR-regulated, cancer-associated lncRNAs from prostate cancer cell lines 
and patient tissue samples.
Results
Analysis of androgen receptor-regulated transcriptome in prostate cancer
To nominate AR-regulated genes (ARGs), RNA-Seq was performed on AR-dependent 
VCaP and LNCaP prostate cancer cell lines that were stimulated with an AR ligand, 
dihydrotestosterone (DHT), for 6 and 24 hours (Supplementary Fig. 1a). 1702 genes were 
identified to be concordantly induced or repressed in VCaP and LNCaP at both time points 
(Fig. 1a, Supplementary Fig. 1b–c, Supplementary Table 1), including over 500 lncRNAs 
(Fig. 1a, Supplementary Fig. 1d); these data indicate that a large portion of the AR 
transcriptome remains uncharacterized.
To differentiate between direct and indirect ARGs, previously published AR chromatin 
immunoprecipitation (ChIP)-seq data from LNCaP and VCaP cells were analyzed32. As 
expected for direct AR targets, increased levels of AR binding at transcription start sites 
(TSS) in both LNCaP and VCaP cells were observed (Supplementary Fig. 1e). The binding 
levels decreased following treatment with an AR antagonist (enzalutamide) (Supplementary 
Fig. 1f–g), and the binding sites revealed a de novo motif identical to the canonical AR 
response element33 (Supplementary Fig. 1h). A total of 987 genes were categorized as direct 
ARGs, including 341 lncRNAs (lncARG) (Supplementary Table 1). Within these genes, we 
observed an enrichment of chromatin marks associated with “open” chromatin (H3K27ac, 
H3K4me1), active promoters (H3K4me3), and transcription (H3K36me3), which, together 
with Pol-II occupancy, are recognized as manifestations of active gene expression 
(Supplementary Fig. 1i). Bromodomain and extra-terminal (BET) family proteins, such as 
BRD4, recognize acetylated histones and have been shown to promote AR transcriptional 
activity32. Consistently, we observed the co-localization of BRD4 and AR protein at 
promoters of direct AR responsive genes and the loss of AR following treatment with a 
bromodomain inhibitor (JQ1) (Supplementary Fig. 1f, i). We further sought to determine 
whether ARGs identified from cell lines were also targeted by AR in normal prostate tissues 
and primary tumors. We leveraged the dataset from Pomerantz et. al and queried for the 
presence of AR peaks within ARG promoters34. Remarkably, the majority of ARG 
promoters were TSS-proximally bound by AR in both tissues and cell lines (Supplementary 
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Fig. 1j–k); conversely, AR-independent genes were distal to AR binding sites 
(Supplementary Fig. 1l).
Finally, we confirmed that the AR-regulated genes were also expressed in human prostate 
tissues. We interrogated RNA-Seq data from normal prostate, clinically-localized PCa (The 
Cancer Genome Atlas, TCGA)35, and metastatic CRPC (Stand Up to Cancer-Prostate 
Cancer Foundation, SU2C–PCF)30 (Fig. 1b). This revealed remarkable heterogeneity in the 
expression of ARGs during prostate cancer progression to metastatic disease. As expected, 
compared to protein-coding genes, non-coding ARGs were detected at lower overall levels 
(Fig. 1c), although ~10% of them showed robust expression of over 10 FPKM on average 
across prostate cancer samples.
ARLNC1 is a prostate lineage-specific lncRNA with elevated expression in cancer
We hypothesized that lncRNAs associated with PCa progression and castration-resistance 
should be either upregulated if they enhance AR signaling or, conversely, downregulated if 
they attenuate AR signaling. Their expression is also expected to be AR-dependent and 
lineage-restricted if they are part of bona fide physiological feedback loops. Accordingly, a 
top-down strategy was developed in order to establish and prioritize clinically-relevant, 
prostate cancer- and lineage-specific lncARGs. First, we identified genes that were both 
directly regulated by AR in VCaP/LNCaP cell lines and upregulated in primary (Fig. 2a) or 
metastatic PCas (Fig. 2b) compared to normal prostate tissues. As expected, canonical AR 
targets, including KLK3, KLK2, and TMPRSS2, were among the most differentially 
expressed protein coding genes. Importantly, this approach highlighted several novel 
lncARGs, including ARLNC1 (ENSG00000260896, PRCAT4710), and validated previously 
identified lncARGs, such as CTBP1-AS36 (Fig. 2a–b). Interestingly, ARLNC1 was found to 
be one of the most differentially expressed AR-regulated genes in both localized and 
metastatic PCa (Fig. 2a–b, Supplementary Fig. 2a–b).
Next, we sought to establish the prostate lineage and cancer specificity of prostate cancer-
associated lncRNAs. We leveraged the MiTranscriptome assembly10, an online resource, to 
interrogate lncRNA expression across a multitude of tissue and tumor types, and we 
calculated Sample Set Enrichment Analysis (SSEA) scores, which indicate the strength of 
cancer and lineage association10. After applying an expression level filter (10 FPKM at the 
95th percentile), we identified 12 of the most prostate lineage- and prostate cancer-specific 
lncRNAs (Fig. 2c, Supplementary Fig. 2c–d); five of these lncRNAs were regulated by AR. 
Across these analyses, ARLNC1 was the top prioritized transcript and thus warranted further 
investigation.
Expression of ARLNC1 was interrogated across cancer and normal tissue RNA-Seq samples 
from TCGA and the Genotype-Tissue Expression (GTEx) project37,38, respectively. In the 
TCGA cohort, ARLNC1 exhibited a highly prostate cancer-specific expression pattern, with 
little to no expression in other tumor types (Fig. 2d). Similarly, in the GTEx normal tissue 
cohort, its expression was limited to the prostate (Supplementary Fig. 2e). Among prostate 
samples, ARLNC1 expression was significantly higher in localized and metastatic prostate 
cancers compared to benign tissues, as assessed by RNA-Seq (Fig. 2d inset) and in situ 
hybridization (Fig. 2e). In an extensive differential expression analysis using 
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MiTranscriptome, ARLNC1 was found to be among the top 1% of transcripts most 
upregulated in prostate cancer and specific to the prostate lineage, with no significant 
associations in other tissues (Supplementary Fig. 2f). Additionally, the protein-coding genes 
that were most correlated with ARLNC1 were found to be associated with prostate cancer 
progression in ONCOMINE concept analyses performed on multiple clinical datasets39 
(Supplementary Fig. 2g). Together, these results confirm that ARLNC1 expression is 
restricted to prostate lineage, elevated in prostate cancer, and associated with AR signaling 
throughout prostate cancer progression.
To functionally characterize ARLNC1, we first identified appropriate prostate cancer cell 
lines with moderate to high levels of ARLNC1 expression using in-house RNA-Seq data 
(Supplementary Fig. 3a). Supporting the association of AR with ARLNC1, ARLNC1 
expression was highly enriched in AR-positive cell lines, with the highest expression in 
MDA-PCa-2b and LNCaP cells. In addition, qPCR analysis for the ARLNC1 transcript also 
demonstrated that this gene was expressed highest in MDA-PCa-2b and LNCaP cell lines 
(Supplementary Fig. 3b). As existing annotations of ARLNC1 (located on chromosome 16) 
predicts the presence of several transcript isoforms that differ in exon and TSS usage, we 
determined the exact structure in MDA-PCa-2b and LNCaP cells, by Random amplification 
of cDNA ends (RACE). A common TSS for ARLNC1 was found in both cell lines, and the 
~2.8 kb transcript isoform was further confirmed by northern blot analysis (Supplementary 
Fig. 3c). Single molecule fluorescent in situ hybridization (smFISH) revealed that 
approximately 100 molecules of ARLNC1 transcripts existed per MDA-PCa-2b cell 
(Supplementary Fig. 3d–e). Using smFISH and qPCR, we also found that ARLNC1 
molecules were distributed equally between the nuclear and cytoplasmic cellular 
compartments (Supplementary Fig. 3f–g).
ARLNC1 transcription is directly regulated by AR
Since ARLNC1 was identified as an AR-regulated lncRNA, we inspected ARLNC1 
promoter region for AR occupancy and identified an androgen-induced AR peak in AR 
ChIP-Seq data from both DHT-stimulated VCaP and LNCaP cells (Fig. 3a). Importantly, 
this AR binding site was also observed in prostate tissue samples and contained a canonical 
androgen response element (ARE)33 (Fig. 3a). These observations were corroborated by 
ChIP-qPCR in MDA-PCa-2b cells, which showed the highest level of ARLNC1 expression 
(Fig. 3b). Considering the observation that ARLNC1 expression is prostate tissue-specific, 
while AR expression is not as much, we searched for additional regulators (transcription 
factors and epigenetic modifiers) of this gene (Supplementary Fig. 4a). Motif analysis of the 
ARLNC1 promoter region identified several transcription factor binding sites, including a 
FOXA1-response element. To further validate ARLNC1 gene regulation by AR and FOXA1, 
we evaluated ARLNC1 transcript levels following AR or FOXA1 knockdown. AR or 
FOXA1 loss resulted in decreased expression of ARLNC1, along with other canonical AR 
target genes that served as positive controls (Fig. 3c, Supplementary Fig. 4b). ChIP-seq and 
ChIP-PCR analysis additionally confirmed the putative FOXA1 binding motif on the 
ARLNC1 promoter (Supplementary Fig. 4c). Together, these observations suggest that 
ARLNC1 is directly regulated by AR and modestly regulated by FOXA1, which, partially 
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explains the tissue-specific expression pattern of ARLNC1, as expression of these two 
factors overlaps nearly exclusively in prostate tissue37,38 (Supplementary Fig. 4d).
ARLNC1 regulates AR signaling
To elucidate the function of ARLNC1 in prostate cancer, we performed gene expression 
profiling of wildtype and ARLNC1-knockdown MDA-PCa-2b cells (Fig. 4a). Gene 
Ontology (GO) pathway enrichment analysis of the differentially expressed genes revealed 
deregulation of four main biological activities: apoptosis, cell proliferation, DNA damage 
response, and androgen signaling (Fig. 4a). A significant decrease in AR target gene 
expression is particularly interesting given the fact that ARLNC1 is regulated by AR, 
suggesting a positive feedback loop between ARLNC1 and AR signaling. To confirm this 
observation, we generated an AR target gene signature from MDA-PCa-2b cells stimulated 
with DHT (Supplementary Fig. 5a, Supplementary Table 2) and performed Gene Set 
Enrichment Analysis (GSEA) using this gene signature (Fig. 4b). Knockdown of ARLNC1 
led to suppression of genes positively regulated by AR and upregulation of genes negatively 
regulated by AR (Fig. 4b–c, Supplementary Fig. 5b). This was further confirmed by AR 
reporter activity assay (Fig. 4d, Supplementary Fig. 5c), as well as qPCR analysis of AR 
target genes (Supplementary Fig. 5d). Interestingly, ARLNC1 knockdown also had a 
significant effect on the mRNA and protein levels of AR (Fig. 4e–f), suggesting direct 
regulation of AR by ARLNC1. We, however, found that ARLNC1 overexpression did not 
affect AR and its signaling cascade (Supplementary Fig. 5e).
In situ co-localization of ARLNC1 and AR transcripts
Non-coding RNAs have been shown to target mRNAs via direct or indirect RNA-RNA 
interaction9,40–42. To identify target mRNAs that could interact with ARLNC1, we 
performed an unbiased prediction of RNA-RNA interactions using IntraRNA43,44. 
Interestingly, the 3’ UTR of the AR transcript was identified as a target of ARLNC1 (Fig. 
5a, Supplementary Fig. 6a). An in vitro RNA-RNA interaction assay between the 3’UTR of 
AR and full-length ARLNC1 confirmed this in silico prediction (Fig. 5b). To evaluate this 
interaction in the context of the cellular environment, multiplexed smFISH for AR and 
ARLNC1 transcripts was performed in MDA-PCa-2b cells. Upon co-staining MDA-PCa-2b 
cells with either AR and a panel of lncRNAs, or ARLNC1 and a panel of mRNAs, we 
observed specific colocalization between AR and ARLNC1 transcripts in the nucleus within 
foci that were typically larger than individual molecules (Fig. 5c–e). The extent of 
colocalization was much higher than that expected from co-incidental colocalization with an 
abundant transcript, such as MALAT1 or GAPDH (Fig. 5c–e). More specifically, 
colocalization typically occurred at a stoichiometry of 2:1 ARLNC1:AR, which accounted 
for ~10–20% of all AR and ARLNC1 transcripts in the cell (Supplementary fig. 6b). 
Furthermore, AR-ARLNC1 colocalization was observed in ARLNC1-positive prostate 
cancer tissues (Fig. 5f–g).
Using an in vitro RNA-RNA binding assay, we identified nucleotides (nt) 700–1300 of 
ARLNC1 to be critical for binding to the AR 3’UTR (Fig. 6a–b). To confirm this 
observation within the cellular context, we ectopically overexpressed different fragments of 
ARLNC1 together with AR in U2OS osteosarcoma cells. In this exogenous system, 
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colocalization between AR and ARLNC1 was once again demonstrated, wherein 
colocalization was dependent on the presence of 700–1300 nt of ARLNC1 (Fig. 6c–d, 
Supplementary Fig. 6c). Furthermore, incubation with antisense oligos (ASOs) that blocked 
the interaction site led to a significant reduction in ARLNC1-AR interaction in vitro and in 
situ (Fig. 6e–f, Supplementary Fig. 6d–e). Decreased AR signaling was also observed 
following blocking of this interaction (Fig. 6g, Supplementary Fig. 6f).
ARLNC1 regulates the cytoplasmic levels of AR transcripts
We then sought to delineate the mechanism of ARLNC1-mediated AR regulation. We first 
monitored the stability of these two transcripts and found that AR and ARLNC1 have 
similar half-lives of ~9 hours (Supplementary Fig. 6g). Because ARLNC1 depletion resulted 
in a striking reduction of AR protein levels, much more than that could be explained by AR 
transcript reduction, we hypothesized that ARLNC1 could affect AR post-transcriptionally. 
To test this hypothesis, we tracked sub-cellular localization of AR transcripts using smFISH 
after depleting ARLNC1. We confirmed successful in situ knockdown of ARLNC1 using 
siRNAs, antisense oligo (ASO), and the blocking oligos that targeted ARLNC1-AR 
interaction (ASO-blocking) in MDA-PCa-2b cells (Supplementary Fig. 6h–i). Quantification 
of the sub-cellular distribution of ARLNC1 suggested that the nuclear fraction of ARLNC1 
was enriched only in the si-ARLNC1 condition (Supplementary Fig. 6j), a result which was 
expected for siRNAs that are typically more functional in the cytosol45. Surprisingly, 
ARLNC1 knockdown or obstruction of the AR-ARLNC1 interaction increased the nuclear 
AR fraction by dramatically decreasing cytoplasmic levels of AR transcript (Fig. 7a–b, 
Supplementary Fig. 6k–l). This observation was further supported by BrU-seq and BrU-
chase-seq, two high-throughput tools that monitor transcript synthesis and stability. Upon 
ARLNC1 knockdown, the synthesis rate of the AR transcript remained the same 
(Supplementary Fig. 6m), while the stability of the transcript decreased, particularly through 
the 3’UTR region (Supplementary Fig. 6n). Taken together, our data suggest that ARLNC1 
regulates the cytoplasmic levels of AR transcripts. Furthermore, the transcriptional coupling 
between AR and ARLNC1 transcripts is mediated by direct interactions which are encoded 
in their sequences.
Inhibition of ARLNC1 delays prostate cancer growth in vitro and in vivo
Having established a role for ARLNC1 in the regulation of AR signaling, we further 
evaluated the biological effects of ARLNC1 in prostate cancer cell lines. GO pathway 
enrichment analysis of the knockdown microarray data showed that ARLNC1-regulated 
genes were involved in cell proliferation and apoptosis (Fig. 4a). Knockdown of ARLNC1 
had a significant effect on the proliferation of AR-dependent MDA-PCa-2b and LNCaP 
cells, but had no effect on AR-negative DU145 and PC3 cells (Fig. 8a, Supplementary Fig. 
7a–b). Knockdown of ARLNC1 also resulted in increased apoptosis in AR-positive prostate 
cancer cells (Fig. 8b, Supplementary Fig. 7c). Importantly, these results translated to effects 
in vivo, as cells expressing shRNA targeting ARLNC1 formed smaller tumors in mice when 
compared to cells expressing non-targeting shRNA (Fig. 8c), thus suggesting that ARLNC1 
is an important survival factor for AR-dependent prostate cancer.
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Since modulation of ARLNC1 expression levels resulted in a striking proliferation 
phenotype, we hypothesized that ARLNC1 inhibition could be used therapeutically for the 
treatment of prostate cancer. Antisense oligos have recently been shown to be effective in 
targeting RNA in vivo46–49, thus, we designed ASOs targeting the ARLNC1 transcript 
(Supplementary Fig. 7d). Transfection of ASOs exhibited strong knockdown efficiency 
(Supplementary Fig. 7e), and ASO-mediated knockdown resulted in similar effects on gene 
expression profiling as siRNA (Fig. 8d–e, Supplementary Fig. 7f). Furthermore, AR-positive 
cells transfected with ARLNC1 ASOs exhibited retarded growth, similar to those treated 
with siRNAs (Fig. 8f). To evaluate the therapeutic potential of ARLNC1 ASOs in vivo, we 
first assessed the cellular free uptake efficiency of ARLNC1 ASOs, a prerequisite for ASO 
therapeutic use. Importantly, several ASOs significantly reduced ARLNC1 levels through 
free uptake (Supplementary Fig. 7g). Free uptake of ARLNC1 ASOs led to a significant 
decrease in the proliferation capacity of MDA-PCa-2b cells in both normal cell culture and 
3D sphere conditions (Supplementary Fig. 7h–j). Treatment of mice bearing MDA-PCa-2b 
xenografts with ARLNC1-targeting ASOs led to significant decreases in tumor growth 
compared to control ASO (Fig. 8g–h, Supplementary Fig. 8a–e). Taken together, these data, 
along with the association of ARLNC1 with aggressive androgen signaling (Supplementary 
Fig. 8f–j), suggest that ARLNC1 plays a critical role in the proliferation of AR-dependent 
prostate cancer and can be effectively exploited as a therapeutic target.
Discussion
As AR signaling remains a significant driver of CRPC pathogenesis, it is imperative to 
generate novel strategies to target this pathway. Even with the addition of enzalutamide or 
abiraterone to CRPC treatment regimens, progression invariably occurs. Exploiting players 
other than AR itself that are pivotal to maintaining the magnitude of the androgen response 
is an alternative approach. Our comprehensive profiling of AR-regulated, prostate cancer-
associated lncRNAs identified the top-ranking candidate ARLNC1 that we functionally 
characterized. We identified a positive feedback loop between ARLNC1 and AR that 
maintains the androgen transcriptional program in AR-positive prostate cancer cells, 
specifically through regulating the cellular levels of AR (Fig. 8i). The mechanism we 
identified echoes previous studies on lncRNAs: 1/2-sbsRNAs42, BACE1-AS9, and TINCR41, 
which highlights the role of lncRNA in increasing or decreasing RNA stability.
As a novel non-coding regulator of AR signaling, ARLNC1 has the potential to be not only 
a mechanistic biomarker, but also a therapeutic target for advanced prostate cancer. In 
addition, acting upstream of AR signaling presents the possibility that targeting ARLNC1 
may afford an additional option to patients that have de novo or acquired resistance to 
therapies targeting AR itself (i.e. enzalutamide or abiraterone). Furthermore, specific 
antisense nucleotides targeting ARLNC1, which we demonstrate to be specifically expressed 
in the prostate, could circumvent undesirable side effects that occur in other tissues with 
exposure to androgen synthesis inhibitors or antiandrogens.
Although we have identified a new node of the AR signaling network that can be 
therapeutically-targeted, the molecular mechanism through which ARLNC1 regulates AR 
transcript levels remains to be fully characterized. At this time, it is unclear whether the 
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physical interaction between the AR 3’UTR and ARLNC1 functions with the aid of 
additional RNA-binding proteins (e.g. HuR) and/or RNAs in vivo50,51. Nonetheless, the 
application of ASOs has ushered in an exciting era that makes it possible to target previously 
“undruggable” molecules directly at the transcript level, such as ARLNC1, which is likely to 
yield promising opportunities in cancer treatment.
Methods
Cell lines
Cell lines were purchased from the American Type Culture Collection (ATCC) and 
maintained using standard media and conditions. All cell lines were genotyped by DNA 
fingerprinting analysis and tested for mycoplasma infection every two weeks. All cell lines 
used in this study were mycoplasma-negative. For androgen stimulation experiments, VCaP 
and LNCaP cells were grown in charcoal-stripped serum containing media for 48 hours and 
then stimulated with 10 nM DHT (Sigma-Aldrich) for 6 or 24 hours.
RNA-Seq
Total RNA was extracted from LNCaP and VCaP cells following DHT treatment, using the 
miRNeasy kit (QIAGEN). RNA quality was assessed using the Agilent Bioanalyzer. Each 
sample was sequenced using the Illumina HiSeq 2000 (with a 100-nt read length) according 
to published protocols52.
RNA-Seq data analysis to identify AR-regulated genes
RNA-Seq data were analyzed as previously described53. Briefly, the strand-specific paired-
end reads were inspected for sequencing and data quality (e.g. insert size, sequencing 
adapter contamination, rRNA content, sequencing error rate). Libraries passing QC were 
trimmed of sequencing adapters and aligned to the human reference genome, GRCh38. 
Expression was quantified at the gene level using the “intersection non-empty” mode54 as 
implemented in featureCounts55 using the Gencode v2256 and/or MiTranscriptome 
assemblies10. All pairwise differential expression analyses were carried out using the voom-
limma approach57,58 with all default parameters. Relative expression levels (FPKMs, 
fragments per kilobase of transcript per million mapped reads) were normalized for 
differences in sequencing depth using scaling factors obtained from the calcNormFactors 
(default parameters) function from edgeR59.
AR-regulated genes (ARGs) were identified from expression data of VCaP and LNCaP cells 
treated with DHT after 6 and 24 hours using three linear models: separate models for each of 
the cell lines treating the two time-points as biological replicates, and a merged model with 
all treated samples as replicates. ARGs were defined as genes that were significant (P value 
< 0.1 and absolute log fold-change > 2) in both separate models and/or the merged model.
Identification of prostate cancer associated protein-coding genes and lncRNAs
Raw RNA-Seq data for primary and metastatic patients were obtained from the TCGA/
PRAD and PCF/SU2C projects, respectively. External transcriptome samples were re-
analyzed using in-house pipelines (see above) to facilitate direct comparisons of expression 
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levels and identification of DEGs. Pan-cancer analyses based on the MiTranscriptome 
assembly10 were leveraged as FPKMs and enrichment scores (SSEA) were computed as part 
of that project. To visualize data, fold changes were computed relative to median expression 
levels estimated across the combined (normal, primary, metastatic) cohorts and subjected to 
unsupervised hierarchical clustering separately within each cohort. Tissue lineage (prostate) 
and prostate cancer-specific genes were identified using the sample set enrichment analysis 
(SSEA) method as previously described10. Briefly, the SSEA test was used to determine 
whether each gene was significantly associated with a set of samples (e.g. prostate cancer), 
or cancer progression in a given lineage (e.g. prostate normal to prostate cancer). The genes 
were ranked according to their strength of association.
Oncomine concept analysis of the ARLNC1 signature
Genes with expression levels significantly correlated with ARLNC1 were separated into 
positively and negatively correlated gene lists. These two lists were then imported into 
Oncomine as custom concepts and queried for association with other prostate cancer 
concepts housed in Oncomine. All the prostate cancer concepts with odds ratio > 2.0 and P-
value < 1 × 10−4 were selected. Top concepts (based on odds ratios) were selected for 
representation. We exported these results as the nodes and edges of a concept association 
network and visualized the network using Cytoscape version 3.3.0. Node positions were 
computed using the Edge-weighted force directed layout in Cytoscape using the odds ratio 
as the edge weight. Node positions were subtly altered manually to enable better 
visualization of Mode labels60.
Chromatin immunoprecipitation (ChIP)-Seq data analysis
ChIP-Seq data from published external and in-house data sets, GSE56288 and GSE55064, 
were reanalyzed using a standard pipeline. Briefly, groomed reads (vendor QC, adapter 
removal) were aligned to the GRCh38 reference genome using STAR settings that disable 
spliced alignment: outFilterMismatchNoverLmax: 0.05, outFilterMatchNmin: 16, 
outFilterScoreMinOverLread: 0, outFilterMatchNminOverLread: 0, alignIntronMax: 1. 
Improperly paired alignments and non-primary alignments were discarded. Peaks were 
called using MACS2 (callpeak --broad --qvalue 0.05 --broad-cutoff 0.05 and callpeak --call-
summits --qvalue 0.05)61 and Q (−n 100000)62. ChIP enrichment plots were computed from 
alignment coverage files (BigWig63) as trimmed (trim=0.05) smooth splines (spar=0.05). 
The baseline (non-specific) ChIP signal was estimated from genomic windows furthest from 
the center of the queried region (peak summit, transcription start site) and subtracted from 
each signal before plotting.
AR binding motif search
Unsupervised motif search was carried out using MEME64. DNA sequences (GRch38) from 
the uni-peak ChIP-Seq regions overlapping promoters (5 kb upstream, 1 kb downstream of 
the assembled or known TSS) of ARGs were used as input to MEME (default parameters).
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ChIP-qPCR assay
AR, FOXA1, or NKX3-1 ChIP was performed following our previous protocol32. 
(Antibodies: AR, Millipore Cat# 06–680; FOXA1, Thermo Fisher Cat# PA5–27157; 
NKX3-1, CST Cat# 83700S.) Quantitative PCR (qPCR) analysis was performed using 
primers listed in Supplementary Table 3. Primers targeting CYP2B7 promoter were 
purchased from CST, Cat #84846.
RNA in situ hybridization (RNA ISH) on tissue microarray
In situ hybridization assays were performed on tissue microarray sections from Advanced 
Cell Diagnostics, Inc. as described previously7. In total, 133 tissue samples were included 
(11 from benign prostate, 85 from localized prostate cancer, and 37 from metastatic prostate 
cancer). ARLNC1 ISH signals were examined in morphologically-intact cells and scored 
manually by a study pathologist, using a previously described expression value scoring 
system65. For each tissue sample, the ARLNC1 product score was averaged across evaluable 
TMA tissue cores. Mean ARLNC1 product scores were plotted in Fig. 2e.
Rapid Amplification of cDNA Ends (RACE)
5’ and 3’ RACE were performed to determine the transcriptional start and termination sites 
of ARLNC1, using the GeneRacer RLM-RACE kit (Invitrogen), according to the 
manufacturer’s instructions.
Northern blot analysis
NorthernMax-Gly Kit (Ambion) was used for ARLNC1 detection following the 
manufacturer’s protocol. Briefly, 20 µg of total RNA was resolved on a 1% agarose glyoxal 
gel and then transferred to nylon membrane (Roche), cross-linked to the membrane (UV 
Stratalinker 1800; Stratagene), and the membrane was pre-hybridized. Overnight 
hybridization was performed with ARLNC1-specific P32-labeled RNA probe. Membranes 
were exposed to HyBlot CL autoradiography film (Denville Scientific). The primer 
sequences used for generating the probes are given in Supplementary Table 3.
RNA isolation and cDNA synthesis
Total RNA from cell lines was isolated using QIAzol Lysis reagent (QIAGEN) and 
miRNeasy kit (QIAGEN) with DNase digestion according to manufacturer’s instructions. 
cDNA was synthesized using Superscript III (Invitrogen) and random primers (Invitrogen).
qRT–PCR analysis
Relative RNA levels determined by qRT–PCR were measured on an Applied Biosystems 
7900HT Real-Time PCR System, using Power SYBR Green MasterMix (Applied 
Biosystems). All of the primers were obtained from Integrated DNA Technologies (IDT), 
and gene-specific sequences are listed in Supplementary Table 3. GAPDH, HMBS, or 
ACTB were used as internal controls for quantification of gene targets. The relative 
expression of RNAs was calculated using ΔΔCt method.
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Cytoplasmic and nuclear RNA purification
Cell fractionation was performed using the NE-PER nuclear extraction kit (Thermo 
Scientific) according to manufacturer’s instructions. RNA was extracted using the previously 
mentioned protocol.
siRNA-mediated knockdown
siRNA oligonucleotides targeting ARLNC1, AR, FOXA1, BRD4, NKX3-1, LSD1, IRF1, 
POU1F1, or EZH2 and a non-targeting siRNA were purchased from Dharmacon. (si-AR-
pool, Cat# L-003400-00–0005; si-FOXA1, Cat# LU-010319-00–0005; si-BRD4, Cat# 
LU-004937-00–0002; si-NKX3-1, Cat# LU-015422-00–0005; si-LSD1, Cat# 
LU-009223-00–0002; si-IRF1, Cat# LU-011704-00–0005; si-POU1F1, Cat# 
LU-012546-00–0005; si-EZH2, Cat# L-004218-00–0005; si-NT, Cat# D-001810-01–05.) 
siRNA sequences for ARLNC1 knockdown are listed in Supplementary Table 3. For AR 
knockdown, two more siRNAs were purchased from Life Technologies (#HSS179972, 
#HSS179973). Transfections with siRNA (50 nM) were performed with Lipofectamine 
RNAiMAX according to the manufacturer’s instructions. RNA and protein were harvested 
for analysis 72 hours after transfection.
ASO-mediated knockdown
Antisense oligos targeting ARLNC1 were obtained from Ionis Pharmaceuticals. 
Transfections with ASOs (50 nM) were performed with Lipofectamine RNAiMAX 
according to the manufacturer’s instructions. RNA and protein were harvested for analysis 
72 hours after transfection.
Gene expression profiling
Total RNA was extracted following the aforementioned protocol. RNA integrity was 
assessed using the Agilent Bioanalyzer. Microarray analysis was carried out on the Agilent 
Whole Human Oligo Microarray platform, according to the manufacturer’s protocol. 
siRNA-mediated knockdown experiments were run in triplicates, comparing knockdown 
samples treated with two independent ARLNC1 siRNAs to samples treated with non-
targeting control siRNA. ASO-mediated knockdown experiments were run in replicates, 
comparing knockdown samples treated with two ARLNC1 ASOs to samples treated with 
non-targeting control. An AR signature was generated using MDA-PCa-2b cells treated with 
10 nM DHT in triplicates.
Analysis of Agilent 44k microarrays was carried out using limma and included background 
subtraction (bc.method=“half”, offset=100) and within-array normalization 
(method=“loess”). Between array quantile normalization of average expression levels (but 
not log-fold changes) was performed using the function normalizeBetweenArrays 
(method=“Aquantile”). Control probes and probes with missing values were excluded from 
further analyses. Probes were annotated to Gencode v22 genes using the mapping 
downloaded from Ensembl (efg_agilent_wholegenome_4×44k_v2). Probes originally 
annotated as AK093002 were used to detect ARLNC1. Differentially-expressed genes 
following ARLNC1 knockdown in MDA-PCA-2b cells were identified from triplicate 
biological repeats using adjusted P value < 0.1 and absolute log fold-change > 0.6 cut-offs. 
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Consensus targets of ARLNC1 knockdown using siRNA and ASOs were identified using a 
merged linear model (all 10 samples treated replicates) and a P value < 0.001 cut-off.
Gene Set Enrichment Analysis
Enrichment analyses for custom and experimentally-derived signatures (i.e. AR targets, 
genes up- and down-regulated following DHT treatment) were carried out using the 
nonparametric GSEA software with all default settings. For Gene Ontology (GO) term 
enrichment, we applied the parametric randomSet66 enrichment statistic to voom-limma 
estimated fold-changes (see above).
Overexpression of ARLNC1
Full-length ARLNC1 was amplified from MDA-PCa-2b cells and cloned into the pCDH 
clone and expression vector (System Biosciences). Insert sequences were validated by 
Sanger sequencing at the University of Michigan Sequencing Core. Full-length sequence for 
ARLNC1 expression is listed in Supplementary Table 4.
Single molecule fluorescent in situ hybridization (smFISH)
smFISH and image analysis were performed as described67,68, Probe sequences targeting 
ARLNC1, PCAT1, DANCR, AR, EZH2 and FOXA1 were designed using the probe design 
software in https://www.biosearchtech.com/stellaris-designer and are listed in 
Supplementary Table 5. TERRA probes were designed as described69. Other probes were 
purchased directly from the LGC-Biosearch. U2-OS cells were seeded in 6-well dishes and 
transfected with ARLNC1-expression vector alone, or in combination with AR expression 
vector, using Fugene-HD (Promega) according to the manufacturer’s protocol. Cells were 
incubated for 24 hours, reseeded into 8-well chambered coverglasses, and were 
formaldehyde-fixed for smFISH (as described above) after 24 hours.
RNA in vitro transcription
Linearized DNA templates for full-length ARLNC1, ARLNC1 fragments, ARLNC1 
deletion, antisense ARLNC1, LacZ, SCHLAP1-AS, THOR, and AR-3’UTR-1–980 were 
synthesized using T7-containing primers. In vitro transcription assays were performed with 
T7 RNA polymerase (Promega) according to the manufacturer’s instructions. For BrU-
labeled RNA synthesis, 5-Bromo-UTP was added to the transcription mix. At the end of 
transcription, DNA templates were removed by Turbo DNase (ThermoFisher), and RNA was 
recovered using RNA Clean and Concentrator Kit (Promega). RNA size and quality was 
further confirmed by the Agilent Bioanalyzer.
RNA-RNA in vitro interaction assay
25 µl of Protein A/G Magnetic Beads (Pierce) were washed twice with RIP Wash Buffer 
(Millipore, Cat# CS203177) before incubating with BrU antibody for one hour at room 
temperature. After antibody conjugation, beads were washed twice with RIP Wash Buffer 
and then resuspended in Incubation Buffer containing RIP Wash Buffer, 17.5 mM EDTA 
(Millipore, Cat# CS203175), and RNase Inhibitor (Millipore, Cat# CS203219). Equal 
amounts (5 pmol) of BrU-labeled RNAs (ARLNC1, ARLNC1-AS, ARLNC1-1–1300, 
Zhang et al. Page 13
Nat Genet. Author manuscript; available in PMC 2018 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
ARLNC1–1301–2786, ARLNC1-1–700, ARLNC1–701–1300, ARLNC1-del-701–1300, 
LacZ, SCHLAP1-AS, THOR) were incubated with beads in Incubation Buffer for two hours 
at 4°C. Following incubation, 2.5 pmol of AR 3’UTR-1–980 RNA fragment were added into 
individual tubes and incubated overnight at 4°C. After incubation, beads were washed six 
times with RIP Wash Buffer. To recover RNA, beads were digested with proteinase K buffer 
containing RIP Wash Buffer, 1% SDS (Millipore, Cat# CS203174), and 1.2 µg/µL proteinase 
K (Millipore, Cat# CS203218) at 55°C for 30 minutes with shaking. After digestion, RNA 
was extracted from supernatant using the miRNeasy kit (QIAGEN), and reverse 
transcription was performed using the Superscript III system (Invitrogen). The amount of 
AR 3’UTR-1–980 recovered in each interaction assay was quantified by qPCR analysis. 
Data were normalized to ARLNC1-AS control, using ΔCt method. We designed ASOs 
blocking the AR-ARLNC1 interaction sites (ASO-Blocking, Ionis Pharmaceuticals) and 
used them in the in vitro interaction assays. Data were normalized to the control ASO, using 
the ΔCt method.
RNA stability assay
LNCaP cells were treated with 5 µg/mL of actinomycin D for various times as indicated. 
RNA was extracted and qRT-PCR was carried out as described above. RNA half-life (t1/2) 
was calculated by linear regression analysis.
Cell proliferation assay
Cells treated with siRNAs or ASOs were seeded into 24-well plates and allowed to attach. 
Cell proliferation was recorded by IncuCyte live-cell imaging system (Essen Biosciences), 
following manufacturer’s instructions.
Apoptosis analysis
Cells were grown in 6-well plates and transfected with nonspecific siRNA or siRNAs 
targeting ARLNC1. Apoptosis analysis was performed 48 hours after transfection, using the 
Dead Cell Apoptosis Kit (Molecular Probes #V13241) according to manufacturer’s 
instructions.
Immunoblot analysis
Cells were lysed in RIPA lysis and extraction buffer (Thermo Scientific #89900) 
supplemented with protease inhibitor cocktail (ROCHE #11836170001). Protein 
concentrations were quantified using the DC protein assay (BIO-RAD), and protein lysates 
were boiled in sample buffer. Protein extracts were then loaded and separated on SDS-PAGE 
gels. Blotting analysis was performed with standard protocols using polyvinylidene 
difluoride (PVDF) membrane (GE Healthcare). Membranes were blocked for 60 minutes in 
blocking buffer (5% milk in a solution of 0.1% Tween-20 in Tris-buffered saline (TBS-T) 
and then incubated overnight at 4°C with primary antibody. After three washes with TBS-T, 
membranes were incubated with HRP-conjugated secondary antibody. Signals were 
visualized with an enhanced chemiluminescence system as described by the manufacturer 
(Thermo Scientific Pierce ECL Western Blotting Substrate). Primary antibodies used were: 
Androgen Receptor (1:1000 dilution, Millipore, #06–680, rabbit), GAPDH (1:5000 dilution, 
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Cell Signaling, #3683, rabbit), PSA (KLK3) (1:5000 dilution, Dako, #A0562, rabbit), and 
cleaved PARP (1:1000 dilution, Cell Signaling, #9542, rabbit).
Androgen receptor reporter gene assay
Dual luciferase reporter assays were performed using Cignal Androgen Receptor Reporter 
Kit (Qiagen) according to the manufacturer’s instructions. Briefly, cells were co-transfected 
with siRNAs (nonspecific, targeting AR or ARLNC1) and reporter vectors (negative control 
or AR reporter), using Lipofectamine 2000 transfection reagent (Thermo Fisher Scientific). 
Forty hours after transfection, DHT (or ethanol vehicle control) was added to induce AR 
signaling. The Dual Luciferase assay was conducted eight hours after DHT stimulation, 
using the Dual Luciferase Reporter Assay System from Promega (Cat #1910). Reporter 
activity was analyzed based on ratio of Firefly/Renilla to normalize for cell number and 
transfection efficiency.
In vivo experiments
All experiments were approved by the University of Michigan Institutional Animal Care and 
Use Committee (IACUC). For tumor generation with shRNA-mediated knockdown, shRNA 
targeting ARLNC1 was cloned in pSIH1-H1-copGFP-T2A–Puro (System Biosciences). 
Lentiviral particles were generated at the University of Michigan Vector Core. LNCaP-AR 
cells were infected with lentivirus expressing ARLNC1 shRNA for 48 hours. Knockdown of 
ARLNC1 was confirmed by qPCR analysis. Male athymic nude mice were randomized into 
two groups at six to eight weeks of age. 5 million cells expressing sh-ARLNC1 or sh-vector 
were injected into bilateral flanks of mice. Caliper measurements were taken in two 
dimensions twice a week by an investigator blinded to the study objective and used to 
calculate tumor volume. The study was terminated when the tumor volume reached 1000 
mm3. For ASO treatment in vivo, six to eight week old male athymic nude mice were 
inoculated subcutaneously with MDA-PCa-2b cells suspended in matrigel scaffold in the 
posterior dorsal flank region (5 million cells/site, two sites/animal). When the mean tumor 
volume reached approximately 150 mm3, mice were randomized into two groups, 
respectively treated with ARLNC1-specific or control ASO. ASOs, dosed 50 mg/kg, were 
subcutaneously injected between the scapulae once daily for three periods of five days 
on/two days off. Tumor size was measured twice per week using a digital caliper by a 
researcher blinded to the study design. Mouse body weights were monitored throughout the 
dosing period. When average tumor size in the control group reached 1500 mm3, mice were 
sacrificed and the primary tumors were excised for weight determination. One-third of the 
resected specimen was placed in 10% formalin buffer, and the remaining tissue was snap 
frozen.
BrU-seq and BrUChase-seq
BrU-seq and BrUChase-seq assays were performed as previously described70,71 with MDA-
PCa-2b cells treated with either si-NT or si-ARLNC1. BrU-labeling was performed for 30 
minutes, and chase experiments were performed for six hours.
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Statistical analysis
For in vivo experiments, power analysis (GPOWER software) performed for each tumor 
type tested to date indicates that the sample size we chose yields a statistical power >90% 
for detection of tumor size reduction of 40%. Sample sizes were not pre-determined for all 
other assays. For in vivo experiments, animals were randomized. Randomization was not 
performed for all other assays. Statistical analyses were performed using Graphpad Prism 
software or using R. Data were presented as either means ± s.e.m. or means ± s.d. All the 
experiments were performed in biological triplicates unless otherwise specified. Statistical 
analyses shown in figures represent two-tailed t-tests, one-way ANOVA, two-way ANOVA, 
or Kruskal-Wallis rank sum test as indicated. P < 0.05 was considered to be statistically 
significant. Details regarding the statistical methods employed during microarray, RNA-Seq, 
and ChIP-Seq data analysis were included in aforementioned methods for bioinformatics 
analyses.
Data availability
RNA-seq and microarray datasets generated from this study have been deposited into Gene 
Expression Omnibus, with accession number: GSE110905. Other data supporting the 
finding of this study are included in the Supplementary Information files.
Code availability
Software for transcriptome meta-assembly and lncRNAs discovery is available at https://
tacorna.github.io/.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Identification of AR regulated genes in prostate cancer
a, The androgen-regulated transcriptome of prostate cancer cells. A heatmap representation 
of the 1702 genes (including 547 lncRNAs) differentially regulated in LNCaP and VCaP 
cells, following 6 and 24 hours of DHT treatment. b, The landscape of transcriptomic 
alterations of prostate cancer progression. A heatmap depicting 1155 protein-coding genes 
and 547 lncRNAs across benign prostate (normal, n = 52 samples), localized (PCa, n = 500 
samples), and metastatic prostate cancer (Mets, n = 100 samples) in the TCGA prostate and 
SU2C–PCF RNA-Seq data, with rows representing genes and columns representing patients. 
Patients were grouped by clinical stages and genes were subject to hierarchical clustering. 
Expression variability is quantified for each gene as a Z-score relative to the mean 
expression in normal prostate samples. c, A heatmap representation of ranked gene 
expression levels in prostate tissues. Canonical prostate-lineage and prostate cancer markers 
are listed. (Upper panel: protein-coding genes. Lower panel: non-coding genes.)
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Fig. 2. Nomination and in situ characterization of ARLNC1 in prostate cancer
a–b, Identification of androgen-regulated transcripts elevated in prostate cancer progression. 
Scatterplots showing AR-regulation and cancer-association of ARGs identified in Fig. 1a. Y-
axis depicts log2-fold change of gene expression upon DHT stimulation, and x-axis 
indicates log2-gene expression level difference between benign (n = 52 samples) and 
localized prostate cancer (n = 500 samples) (a), or expression level differences between 
benign (n = 52 samples) and metastatic prostate cancer (n = 100 samples) (b). Significant 
genes with log2 fold-change > 1 were ranked according to the combined P values (limma 
moderated t-test). c, Nomination of prostate cancer- and lineage- associated lncRNAs based 
on expression levels. Scatterplot shows the expression level, prostate tissue specificity, and 
prostate cancer association of lncRNAs. Expression level is the FPKM value at the 95th 
percentile across TCGA prostate samples (total n = 7,256 samples). Average cancer and 
lineage associations are represented by the percentile rank for each gene in SSEA analysis. 
d, Relative expression (FPKM) of ARLNC1 across different cancer types in the TCGA 
cohort. Inset: relative expression (FPKM) of ARLNC1 across benign (n = 52 samples), 
localized (n = 500 samples), and metastatic (n = 100 samples) prostate cancer. PCa vs. 
Normal: ****P < 2.2e-16; Mets vs. Normal: ****P = 2.6e-7 (two-sided t-test). Box-plot 
definition: center - median, box limits 1st and 3rd quartile, whiskers follow the 1.5 rule. eIn 
situ hybridization of ARLNC1 in human prostate cancer tissue microarray. Representative 
ARLNC1 staining is shown for benign prostate, localized, and metastatic prostate cancer 
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tissue. Bar plot represents mean ARLNC1 expression scores across benign (n = 11), 
localized (n = 85), and metastatic (n = 37) tissues, with vertical bars indicating bootstrapped 
95% CI of the means. Significance was calculated by a Kruskal-Wallis rank sum test.
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Fig. 3. ARLNC1 is directly regulated by AR
a, AR ChIP-Seq in prostate cancer cell lines and tissues. Normalized ChIP-Seq enrichment. 
Top, AR or control (IgG) ChIP-Seq results across the ARLNC1 locus in LNCaP and VCaP 
cells with vehicle (ethanol) treatment or DHT treatment. Bottom, AR ChIP-Seq in benign 
prostate and clinically-localized prostate cancer tissue. b, ChIP-qPCR in MDA-PCa-2b cells 
showing AR or IgG enrichment (ChIP/input) over ARLNC1 promoter region (Primer 1) or 
control region (Primer 2). Error bars represent mean ± s.e.m. (n = 3 biologically independent 
samples). ***Adjusted P < 0.0001, ns: P = 0.5746, compared to control Primer 2, by 
ANOVA analysis with Sidak correction for multiple comparisons. Top: schematic of 
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amplicon locations for ChIP-qPCR validation. cAR and AR target gene (ARLNC1, 
TMPRSS2, SLC45A3, and KLK3) expression in MDA-PCa-2b cells transfected with 
control siRNA (si-NT) or siRNAs against AR (si-AR-pool, si-AR-1, si-AR-2). Mean ± 
s.e.m. are shown, n = 3 biologically independent samples. ***P = 0.0001 determined by 
ANOVA with Dunnett’s multiple comparisons test.
Zhang et al. Page 24
Nat Genet. Author manuscript; available in PMC 2018 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 4. ARLNC1 loss attenuates AR signaling
a, Gene expression profiling for ARLNC1 knockdown in MDA-PCa-2b cells (n = 3 
biologically independent cell cultures for each siRNA). The chart presents top enriched 
pathways upon ARLNC1 knockdown, identified using Gene Ontology (GO) enrichment 
analysis (RandomSet test). b, Gene Set Enrichment Analysis (GSEA) showing significant 
enrichment of ARLNC1- regulated gene set with respect to the AR target gene sets (n= 3 
independent gene expression profiles). Shown are the enrichment plots for gene sets 
consisting of genes positively regulated by AR (upper panel), and genes negatively regulated 
by AR (lower panel). c, Comparison of ARLNC1-regulated and AR target genes based on 
RNA-seq following knockdown of AR and ARLNC1. Significant genes and their log-fold 
changes in either of the conditions are shown (n= 2 independent cell cultures per-condition). 
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Combined significance levels, determined by limma moderated t-test (across both 
knockdowns) are indicated by circle size. d, siRNA knockdown of ARLNC1 in MDA-
PCa-2b cells impairs AR signaling by AR reporter gene assay. siRNA against AR serves as a 
positive control for inhibition of AR signaling. Mean ± s.e.m. are shown, n = 3 biologically 
independent cell cultures. **P < 0.01, ***P = 0.0001 determined by ANOVA with Dunnett 
correction. e, qRT–PCR analysis of ARLNC1 and AR in MDA-PCa-2b cells transfected 
with siRNAs against ARLNC1, AR, EZH2, or non-specific control (NT). siRNA against AR 
serves as a positive control for inhibited AR signaling, while siRNA against EZH2 serves as 
a negative control. Mean ± s.e.m. are shown, n = 3. **P < 0.01, ***P = 0.0001 determined 
by ANOVA with Dunnett correction. f, Immunoblot of AR, PSA, and GAPDH in MDA-
PCa-2b cells transfected with siRNAs against ARLNC1, AR, EZH2, or non-specific control 
(NT). Experiments were repeated 3 times independently with similar results. Uncropped 
images are shown in Supplementary Fig. 9.
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Fig. 5. In situ co-localization between AR mRNA and ARLNC1 in prostate cancer cells
a, Schematic of predicted RNA-RNA interaction between ARLNC1 and 3’UTR of ARb, 
ARLNC1 interacts with AR 3’UTR in an in vitro RNA-RNA interaction assay. Compared to 
a panel of control RNAs (ARLNC1 antisense, LacZ, SCHLAP1-AS, THOR), ARLNC1 
binds to AR 3’UTR-1-980 with high affinity. Binding affinity was quantified by qPCR 
analysis of AR 3’UTR. Data were normalized to ARLNC1-AS control. Mean ± s.e.m. are 
shown, n = 3. **P < 0.001 by two-tailed Student’s t-test. c–e, smFISH depiction of AR-
ARLNC1 colocalization in situ. Representative pseudocolored images of MDA-PCa-2b cell 
nuclei (c) stained for the appropriate endogenous (endo) transcripts (green, red) and DAPI 
(nucleus, blue). Scale bar, 5 µm. Quantification of the percentage of AR or ARLNC1 
molecules co-localizing with a panel of lncRNAs (d) or mRNAs (e) respectively. Orange 
circles represent regions of colocalization. Center line and whiskers depict the median and 
Zhang et al. Page 27
Nat Genet. Author manuscript; available in PMC 2018 November 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
range respectively and box extends from 25th to 75th percentiles (n= 50 cells for each sample 
aggregated from 3 independent experiments). ***P < 0.0001 by two-tailed Student’s t-test. 
f–g, Representative pseudo-colored images of ARLNC1 positive prostate cancer tissues (f) 
stained with DAPI (nucleus, blue) and AR (green), HMBS (red), or ARLNC1 (red) 
transcripts (smFISH). Scale bar, 25 µm. Inset, 5.5×5.5 µm2 zoomed-in view of box within 
large panel. Quantification of the percentage of AR molecules (g) colocalizing with HMBS 
or ARLNC1 is also depicted in box plot. Center line and whiskers depict the median and 
range respectively and box extends from 25th to 75th percentiles (n = 15 field-of-views for 
each sample aggregated from 3 independent tissues). **P < 0.001 by two-tailed Student’s t-
test.
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Fig. 6. Identification of ARLNC1 fragment mediating RNA-RNA interaction with AR mRNA
a, In vitro RNA-RNA interaction assay identifies nucleotides 700–1300 on ARLNC1 as 
critical binding sites to AR 3’UTR-1-980. ARLNC1 fragments covering nucleotides 700–
1300 display comparable or higher AR 3’UTR-binding affinity compared to ARLNC1-S, 
with ARLNC1-700–1300 exhibiting the highest binding affinity. Data were normalized to 
ARLNC1-AS control. Mean ± s.e.m. are shown, n = 3. ***Adjusted P = 0.0001, determined 
by ANOVA with Dunnett’s multiple comparisons test. b, Deletion of nucleotides 700–1300 
on ARLNC1 results in impaired binding to AR 3’UTR, as shown by in vitro RNA-RNA 
interaction assay. Data were normalized to ARLNC1-AS control. Mean ± s.e.m. are shown, 
n = 3. ***P = 0.0001, **P = 0.0003 by two-tailed Student’s t-test. c–d, smFISH shows that 
700–1300nt in ARLNC1 is important for colocalization in situc, Representative pseudo-
colored images of U2-OS cells stained for DAPI (nucleus, blue), ARLNC1 (green) and AR 
transcripts (red). Scale bar, 10 µm. Inset, 10×10 µm2 zoomed-in view of orange box in the 
image. d, Quantification of the percent of AR molecules colocalizing with various ARLNC1 
fragments. Center line and whiskers depict the median and range respectively and box 
extends from 25th to 75th percentiles (n= 50 cells for each sample aggregated from 3 
independent experiments). ***P < 0.0001 by two-tailed Student’s t-test. NS, not significant. 
e, Antisense oligos targeting sites 700–1300 on ARLNC1 transcript (Blocking ASO pool) 
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inhibit ARLNC1 interaction with AR 3’UTR. In vitro RNA-RNA interaction assays were 
performed using ARLNC1 and AR 3’UTR, with the addition of blocking ASO pool or 
control ASO. Data were normalized to control ASO. Mean ± s.e.m. are shown, n = 3. P = 
0.0014 by two-tailed Student’s t-test. f, smFISH shows that ASOs targeting 700–1300nt on 
ARLNC1 transcript (ASO-Blocking) inhibit ARLNC1 colocalization with AR, in situ. 
Quantification of the percent of AR transcripts colocalizing with ARLNC1 after various 
treatments in MDA-PCa-2b cells. Center line and whiskers depict the median and range and 
box extends from 25th to 75th percentiles (n= 50 cells for each sample aggregated from 3 
independent experiments). P value computed by two-tailed Student’s t-test. g, qPCR analysis 
of ARLNC1, AR transcript and AR signaling genes (KLK2, KLK3, NKX3-1, TMPRSS2, 
FKBP5) in MDA-PCa-2b cells transfected with control or blocking ASOs targeting the 
interaction sites between ARLNC1 and AR 3’UTR. Mean ± s.e.m. are shown, n = 3. 
Significance was determined by two-tailed Student’s t-test.
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Fig. 7. ARLNC1 regulates cytoplasmic level of AR transcript
a, ARLNC1 regulates AR post-transcriptionally by specifically affecting cytoplasmic AR 
mRNA. Representative pseudo-colored images of MDA-PCa-2b cells stained for DAPI 
(nucleus, blue) and AR (gray) after treatment with siRNA against AR (si-AR), siRNA 
against ARLNC1 (si-ARLNC1–3), ASO against ARLNC1 (ASO-ARLNC1-1) or blocking 
ASO against AR-ARLNC1 colocalizing segment (ASO-Blocking). Scale bar, 5 µm. 
Quantification of knockdown are represented in Supplementary Fig. 6(k–l). b, Fractional 
column plots depicting the nucleo-cytoplasmic distribution of AR mRNA after various 
treatment conditions in (a), as computed using smFISH. Mean ± s.e.m. are shown, n = 3 
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independent experiments and 60 cells analyzed for each sample. P values were computed by 
comparing to si-NT or ASO-Control treated cells, by two-tailed Student’s t-test.
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Fig. 8. ARLNC1 as a therapeutic target in AR-positive prostate cancer models
a, siRNA knockdown of ARLNC1 in vitro in AR-positive prostate cancer cell lines (MDA-
PCa-2b and LNCaP) inhibits cell proliferation. The AR-negative prostate cell line DU145 
serves as negative control. Mean ± s.d. are shown, n = 6 independent cell cultures per group, 
**Adjusted P = 0.0001 compared to si-NT treated cells, by one-way ANOVA analysis with 
Dunnett’s multiple comparison test; ns: not significant. b, ARLNC1 loss leads to increased 
apoptosis as shown by western blot analysis of PARP and cleaved PARP in LNCaP cells 
following ARLNC1 knockdown. The experiment was repeated independently for 3 times 
with similar results. Uncropped images are shown in Supplementary Fig. 9. c, Tumor growth 
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of LNCaP-AR cells expressing shRNA targeting ARLNC1 or shRNA vector. Mean ± s.e.m. 
are shown. n = 10 independent tumors, ***P < 0.0001 and **P = 0.0007, significance tested 
by two-tailed Student’s t-test. d, Gene expression profiling for siRNA-mediated or ASO-
mediated ARLNC1 knockdown in MDA-PCa-2b cells. Numbers above the heatmap 
represent the specific microarray replicates. e, qRT–PCR analysis of ARLNC1, AR, and AR 
targets (KLK2, KLK3, FKBP5, and STEAP2) in MDA-PCa-2b cells transfected with ASOs 
against ARLNC1. Data were normalized to a housekeeping gene and the levels in control 
ASO-treated cells were set to 1. Mean ± s.e.m. are shown, n = 3. Adjusted P values 
determined by one-way ANOVA with Dunnett correction for multiple comparisons. f, 
Transfection of ASOs targeting ARLNC1 in AR-positive MDA-PCa-2b cells inhibits cell 
proliferation. AR-negative prostate cell line PNT2 serves as negative control. Mean ± s.e.m. 
are shown, n = 6 independent cell cultures per treatment group. *Adjusted P = 0.0112, 
**Adjusted P = 0.0065, ns: not significant; compared to control-ASO group by one-way 
ANOVA analysis with Dunnett correction for multiple comparisons. g–h, Effect of ASO 
treatment on the growth of MDA-PCa-2b xenografts in male NOD-SCID mice, with control 
ASO (n = 15) or ARLNC1 ASO (n = 13) treatment subcutaneously at 50 mg/kg, five times 
per week for three weeks. Tumors were measured by caliper bi-weekly (g) and tumor 
weights were measured at end point (h). Mean ± s.d. are shown. *P = 0.0251, ***P < 
0.0001; compared to control ASO by two-tailed Student’s t-test. i, Model depicting positive 
feedback loop between ARLNC1 and AR that is critical for prostate cancer growth.
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